Galapagos Stock Price, News & Analysis (NASDAQ:GLPG)

$115.02 -0.55 (-0.48 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$115.57
Today's Range$114.65 - $116.73
52-Week Range$67.30 - $121.09
Volume91,328 shs
Average Volume103,823 shs
Market Capitalization$5.87 billion
P/E Ratio-125.62
Dividend YieldN/A
Beta1.85

About Galapagos (NASDAQ:GLPG)

Galapagos logoGalapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLPG
CUSIPN/A
Phone321-534-2900

Debt

Debt-to-Equity RatioN/A
Current Ratio8.05%
Quick Ratio8.05%

Price-To-Earnings

Trailing P/E Ratio-125.618199802176
Forward P/E Ratio-43.90
P/E GrowthN/A

Sales & Book Value

Annual Sales$165.09 million
Price / Sales35.49
Cash Flow$1.37 per share
Price / Cash84.07
Book Value$18.15 per share
Price / Book6.34

Profitability

Trailing EPS($0.92)
Net Income$59.76 million
Net Margins-22.26%
Return on Equity-4.64%
Return on Assets-3.45%

Miscellaneous

Employees508
Outstanding Shares50,940,000

Galapagos (NASDAQ:GLPG) Frequently Asked Questions

What is Galapagos' stock symbol?

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

When will Galapagos make its next earnings announcement?

Galapagos is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for Galapagos.

Where is Galapagos' stock going? Where will Galapagos' stock price be in 2018?

8 brokerages have issued 12 month price targets for Galapagos' shares. Their forecasts range from $98.00 to $124.00. On average, they expect Galapagos' share price to reach $115.17 in the next twelve months. View Analyst Ratings for Galapagos.

What are Wall Street analysts saying about Galapagos stock?

Here are some recent quotes from research analysts about Galapagos stock:

  • 1. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (1/25/2018)
  • 2. Stifel Nicolaus analysts commented, "Aurinia reported 2Q17 financial results in an after market close press release." (8/11/2017)
  • 3. BTIG Research analysts commented, "Supports Thesis for Minimal Function CF Patients Yesterday, Vertex (VRTX, Not Rated) provided top-line results of the first triplet combination studies for Cystic Fibrosis patients with minimal function mutations, which represents 1/3 of the total patient population. Importantly, the triplet combinations also demonstrated improvements with the F508del homozygous population that exceed the clinical benefit of Orkambi. Overall, this first data for triplet therapies provides positive support for the use of two CFTR correctors within one daily regimen. The results from VRTX’s studies are positive for GLPG’s efforts conceptually, but given GLPG’s limited dataset to date, we continue to think that efforts within CF are a ‘show-me’ story. We maintain our Buy rating and $98 PT.   X-440 and VX-152 Triplet Combinations set a new hurdle rate for clinical efficacy: Although the timespans were relatively short, with 29 days studied with VX-440 and 15 days with VX-152, the +9.5% and +7.3% respective improvements of ppFEV1 are impressive within the F508del homozygous population given the study design had a 4 week run-in period with tezacaftor and ivacaftor. Furthermore, the statistically significant improvements in ppFEV1 in both VX-440 and VX-152 studies within the F508del/Min patient population is unprecedented, underscored by the previous failure of the tezacaftor + ivacaftor combination study." (7/20/2017)
  • 4. Cowen Inc analysts commented, "GLPG provided a broad pipeline update at an R&D day." (6/21/2017)

Who are some of Galapagos' key competitors?

Who are Galapagos' key executives?

Galapagos' management team includes the folowing people:

  • Onno van de Stolpe, Chief Executive Officer, Executive Director, Member of the Executive Committee (Age 58)
  • Bart Filius, Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer
  • Piet Wigerinck, Member of the Executive Committee, Chief Scientific Officer
  • Elizabeth Goodwin, VP Corporate Communications & Investor Relations
  • Walid Abi-Saab, Member of the Executive Committee, Chief Medical Officer
  • Andre Hoekema, Member of the Executive Committee, Chief Business Officer
  • Rajesh Parekh, Non-Executive Chairman of the Board (Age 48)
  • Harrold van Barlingen, Non-Executive Director (Age 52)
  • Katrine Bosley, Independent Non-Executive Director
  • Werner Cautreels, Non-Executive Independent Director (Age 65)

When did Galapagos IPO?

(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who owns Galapagos stock?

Galapagos' stock is owned by many different of institutional and retail investors. Top institutional investors include Sands Capital Management LLC (3.92%), BlackRock Inc. (0.68%), Farallon Capital Management LLC (0.57%), Renaissance Technologies LLC (0.46%), Rock Springs Capital Management LP (0.36%) and Jane Street Group LLC (0.27%). View Institutional Ownership Trends for Galapagos.

Who sold Galapagos stock? Who is selling Galapagos stock?

Galapagos' stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Renaissance Technologies LLC, Rock Springs Capital Management LP, Citadel Advisors LLC, HBK Investments L P, Deutsche Bank AG, Goldman Sachs Group Inc. and Castleark Management LLC. View Insider Buying and Selling for Galapagos.

Who bought Galapagos stock? Who is buying Galapagos stock?

Galapagos' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Jane Street Group LLC, Farallon Capital Management LLC, Millennium Management LLC, Arrowstreet Capital Limited Partnership, Tekla Capital Management LLC, Alliancebernstein L.P. and Victory Capital Management Inc.. View Insider Buying and Selling for Galapagos.

How do I buy Galapagos stock?

Shares of Galapagos can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galapagos' stock price today?

One share of Galapagos stock can currently be purchased for approximately $115.02.

How big of a company is Galapagos?

Galapagos has a market capitalization of $5.87 billion and generates $165.09 million in revenue each year. The biotechnology company earns $59.76 million in net income (profit) each year or ($0.92) on an earnings per share basis. Galapagos employs 508 workers across the globe.

How can I contact Galapagos?

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]


MarketBeat Community Rating for Galapagos (GLPG)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  359
MarketBeat's community ratings are surveys of what our community members think about Galapagos and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Galapagos (NASDAQ:GLPG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.88
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $115.17$115.17$115.17$97.83
Price Target Upside: 0.16% upside23.32% upside23.32% upside20.69% upside

Galapagos (NASDAQ:GLPG) Consensus Price Target History

Price Target History for Galapagos (NASDAQ:GLPG)

Galapagos (NASDAQ:GLPG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018BTIG ResearchReiterated RatingBuy$118.00HighView Rating Details
10/29/2017Stifel NicolausReiterated RatingBuy$120.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$92.00 -> $123.00N/AView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$98.00MediumView Rating Details
8/11/2017NomuraBoost Price TargetBuy$108.00 -> $124.00LowView Rating Details
8/10/2017CowenReiterated RatingBuyMediumView Rating Details
7/7/2017Janney Montgomery ScottUpgradeSell -> NeutralLowView Rating Details
6/22/2017InstinetReiterated RatingBuy$121.00 -> $108.00LowView Rating Details
10/18/2016Goldman Sachs GroupUpgradeNeutral -> BuyN/AView Rating Details
6/17/2016Credit Suisse GroupReiterated RatingHold$48.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Galapagos (NASDAQ:GLPG) Earnings History and Estimates Chart

Earnings by Quarter for Galapagos (NASDAQ:GLPG)

Galapagos (NASDAQ GLPG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018($0.71)N/AView Earnings Details
10/24/2017Q3 2017($0.78)($0.85)$15.85 million$39.16 millionViewN/AView Earnings Details
7/31/2017Q2 2017($0.91)($0.81)$14.80 million$36.45 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.50)($0.31)$31.81 million$42.51 millionViewN/AView Earnings Details
2/24/2017Q4 2016$0.22$1.05$77.67 million$93.43 millionViewN/AView Earnings Details
10/26/2016Q3 2016($0.82)($0.58)$28.50 million$18.16 millionViewN/AView Earnings Details
7/29/2016Q2 2016($0.11)$32.38 millionViewN/AView Earnings Details
4/28/2016Q1 2016$0.87$16.33 millionViewN/AView Earnings Details
3/23/2016Q4 2015($1.71)$14.84 millionViewN/AView Earnings Details
11/13/2015Q3($0.80)$11.46 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Galapagos (NASDAQ:GLPG) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.62 EPS
Next Year EPS Consensus Estimate: $-2.95 EPS

Dividends

Dividend History for Galapagos (NASDAQ:GLPG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galapagos (NASDAQ GLPG)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Galapagos (NASDAQ GLPG) News Headlines

Source:
DateHeadline
Galapagos delivered in 2017Galapagos delivered in 2017
finance.yahoo.com - February 22 at 4:56 PM
MorphoSys and Galapagos Present Results from a...MorphoSys and Galapagos Present Results from a...
www.benzinga.com - February 17 at 4:22 PM
Galapagos and MorphoSys present results from a...Galapagos and MorphoSys present results from a...
www.benzinga.com - February 17 at 8:54 AM
Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San DiegoGalapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego
feeds.benzinga.com - February 17 at 4:16 AM
Galapagos (GLPG) Set to Announce Quarterly Earnings on ThursdayGalapagos (GLPG) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - February 15 at 2:56 AM
Galapagos NV (GLPG) Given Consensus Rating of "Buy" by AnalystsGalapagos NV (GLPG) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 9 at 5:50 PM
Galapagos (GLPG) "Buy" Rating Reiterated at BTIG ResearchGalapagos' (GLPG) "Buy" Rating Reiterated at BTIG Research
www.americanbankingnews.com - February 8 at 7:50 AM
Galapagos (GLPG) Upgraded by BidaskClub to "Buy"Galapagos (GLPG) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - January 31 at 11:30 PM
Galapagos (GLPG) Downgraded by Zacks Investment Research to "Strong Sell"Galapagos (GLPG) Downgraded by Zacks Investment Research to "Strong Sell"
www.americanbankingnews.com - January 28 at 11:40 AM
3 Promising Stocks to Buy in 20183 Promising Stocks to Buy in 2018
finance.yahoo.com - January 26 at 9:20 AM
Jefferies Group Comments on Galapagos NVs FY2017 Earnings (GLPG)Jefferies Group Comments on Galapagos NV's FY2017 Earnings (GLPG)
www.americanbankingnews.com - January 24 at 6:56 AM
Galapagos NV (GLPG) Given Average Rating of "Hold" by BrokeragesGalapagos NV (GLPG) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 15 at 6:44 PM
Galapagos Reports Topline Data From Osteoarthritis StudyGalapagos Reports Topline Data From Osteoarthritis Study
www.zacks.com - January 8 at 9:59 AM
Galapagos NV: Positive topline results with GLPG1972 in osteoarthritis patientsGalapagos NV: Positive topline results with GLPG1972 in osteoarthritis patients
www.finanznachrichten.de - January 7 at 5:31 PM
Positive topline results with GLPG1972 in osteoarthritis patientsPositive topline results with GLPG1972 in osteoarthritis patients
finance.yahoo.com - January 7 at 5:31 PM
Galapagos NV (GLPG) Provides Update on Cystic Fibrosis ProgramsGalapagos NV (GLPG) Provides Update on Cystic Fibrosis Programs
www.streetinsider.com - January 4 at 5:12 PM
Galapagos NV (GLPG) Provides Update on Cystic Fibrosis Programs - StreetInsider.comGalapagos NV (GLPG) Provides Update on Cystic Fibrosis Programs - StreetInsider.com
www.streetinsider.com - January 4 at 9:36 AM
Galapagos NV (GLPG): FLAMINGO Results Kick Off A Data Rich 2018 - Nomura - StreetInsider.comGalapagos NV (GLPG): FLAMINGO Results Kick Off A Data Rich 2018 - Nomura - StreetInsider.com
www.streetinsider.com - January 4 at 9:36 AM
Update on progress in cystic fibrosis programsUpdate on progress in cystic fibrosis programs
finance.yahoo.com - January 2 at 6:30 PM
Galapagos (GLPG) Stock Rating Upgraded by BidaskClubGalapagos (GLPG) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 30 at 2:54 PM
Galapagos (GLPG) Cut to Sell at Zacks Investment ResearchGalapagos (GLPG) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - December 27 at 11:38 PM
Contrasting Galapagos (GLPG) and Bioline RX (BLRX)Contrasting Galapagos (GLPG) and Bioline RX (BLRX)
www.americanbankingnews.com - December 23 at 1:12 PM
Galapagos NV (GLPG) Given Consensus Rating of "Hold" by BrokeragesGalapagos NV (GLPG) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 21 at 6:06 PM
ETFs with exposure to Galapagos NV : December 19, 2017ETFs with exposure to Galapagos NV : December 19, 2017
finance.yahoo.com - December 19 at 5:11 PM
Galapagos NV (GLPG) Set to Open Higher Following Opt-in on Co-promotion of Filgotinib with Gilead (GILD) - StreetInsider.comGalapagos NV (GLPG) Set to Open Higher Following Opt-in on Co-promotion of Filgotinib with Gilead (GILD) - StreetInsider.com
www.streetinsider.com - December 15 at 10:03 AM
Galapagos elects to co-promote filgotinib with Gilead in Europe - Seeking AlphaGalapagos elects to co-promote filgotinib with Gilead in Europe - Seeking Alpha
seekingalpha.com - December 14 at 5:44 PM
Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countriesGalapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries
finance.yahoo.com - December 14 at 5:44 PM
Contrasting Galapagos (GLPG) and The CompetitionContrasting Galapagos (GLPG) and The Competition
www.americanbankingnews.com - December 13 at 11:16 AM
Galapagos to enter NASDAQ Biotech Index Brussels Stock ... - GlobeNewswire (press release)Galapagos to enter NASDAQ Biotech Index Brussels Stock ... - GlobeNewswire (press release)
globenewswire.com - December 11 at 10:23 AM
Galapagos to enter NASDAQ Biotech IndexGalapagos to enter NASDAQ Biotech Index
feeds.benzinga.com - December 11 at 2:06 AM
ETFs with exposure to Galapagos NV : December 7, 2017ETFs with exposure to Galapagos NV : December 7, 2017
finance.yahoo.com - December 7 at 5:38 PM
Galapagos (GLPG) Downgraded to Sell at ValuEngineGalapagos (GLPG) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - December 3 at 12:44 PM
Galapagos (GLPG) Downgraded by BidaskClub to "Strong Sell"Galapagos (GLPG) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - December 2 at 1:26 PM
Galapagos NV (GLPG) Receives Consensus Recommendation of "Buy" from AnalystsGalapagos NV (GLPG) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 26 at 6:14 PM
Galapagos increases share capital through warrant exercisesGalapagos increases share capital through warrant exercises
feeds.benzinga.com - November 23 at 4:23 PM
Galapagos NV (GLPG) Begins Phase 1 Study with Novel CF Corrector GLPG3221 - StreetInsider.comGalapagos NV (GLPG) Begins Phase 1 Study with Novel CF Corrector GLPG3221 - StreetInsider.com
www.streetinsider.com - November 22 at 12:09 AM
Galapagos NV (GLPG) Receives "Buy" Rating from BTIG ResearchGalapagos NV (GLPG) Receives "Buy" Rating from BTIG Research
www.americanbankingnews.com - November 21 at 1:16 PM
Reviewing Galapagos NV (GLPG) & The CompetitionReviewing Galapagos NV (GLPG) & The Competition
www.americanbankingnews.com - November 19 at 11:24 PM
ALBATROSS with GLPG2222 shows positive clinical results in CF patients - GlobeNewswire (press release)ALBATROSS with GLPG2222 shows positive clinical results in CF patients - GlobeNewswire (press release)
globenewswire.com - November 19 at 6:08 PM
ALBATROSS with GLPG2222 shows positive clinical results in CF patientsALBATROSS with GLPG2222 shows positive clinical results in CF patients
feeds.benzinga.com - November 19 at 5:49 PM
ADRDs Underlying Holdings Could Mean 10% Gain PotentialADRD's Underlying Holdings Could Mean 10% Gain Potential
www.nasdaq.com - November 14 at 7:41 PM
Galapagos: Strong Buy From Europe - Seeking AlphaGalapagos: Strong Buy From Europe - Seeking Alpha
seekingalpha.com - November 8 at 8:05 AM
Galapagos: Strong Buy From Europe - Seeking AlphaGalapagos: Strong Buy From Europe - Seeking Alpha
seekingalpha.com - November 8 at 8:05 AM
Galapagos NV (GLPG): Thoughts From NACFC - Stifel - StreetInsider.comGalapagos NV (GLPG): Thoughts From NACFC - Stifel - StreetInsider.com
www.streetinsider.com - November 8 at 8:05 AM
Galapagos NV (GLPG): Thoughts From NACFC - Stifel - StreetInsider.comGalapagos NV (GLPG): Thoughts From NACFC - Stifel - StreetInsider.com
www.streetinsider.com - November 8 at 8:05 AM
Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 studyConsistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study
feeds.benzinga.com - November 5 at 9:55 AM
Galapagos NV :GLPG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Galapagos NV :GLPG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 9:59 AM
Galapagos NV: Galapagos moving forward in CF programs at NACFC 2017Galapagos NV: Galapagos moving forward in CF programs at NACFC 2017
www.finanznachrichten.de - November 2 at 8:50 PM
Galapagos moving forward in CF programs at NACFC 2017Galapagos moving forward in CF programs at NACFC 2017
feeds.benzinga.com - November 2 at 3:31 AM
Galapagos NV (GLPG) Given Average Rating of "Buy" by BrokeragesGalapagos NV (GLPG) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 1 at 5:34 PM

SEC Filings

Galapagos (NASDAQ:GLPG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Galapagos (NASDAQ:GLPG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Galapagos (NASDAQ GLPG) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.